<SEC-DOCUMENT>0001176256-16-000598.txt : 20160630
<SEC-HEADER>0001176256-16-000598.hdr.sgml : 20160630
<ACCEPTANCE-DATETIME>20160630171453
ACCESSION NUMBER:		0001176256-16-000598
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20160615
FILED AS OF DATE:		20160630
DATE AS OF CHANGE:		20160630

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aurinia Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001600620
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36421
		FILM NUMBER:		161743896

	BUSINESS ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
		BUSINESS PHONE:		250-708-4272

	MAIL ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>160630aurinia6kmcr.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER DATED JUNE 30, 2016
<TEXT>
<HTML>
<HEAD>
<TITLE>Filed by e3 Filing, Computershare 1-800-973-3274 - AURINIA PHARMACEUTICALS INC. - Form 6-K</TITLE>
</HEAD>
<BODY bgcolor="#ffffff" style="font-family: 'Times New Roman';font-size: 10pt;">
<A name="page_1"></A>
<HR SIZE=3 noShade>
<BR>
<BR>
<a name="_bclPageBorder1"></a>
<DIV style="PADDING-LEFT: 0%; PADDING-RIGHT: 0%">
  <P style="TEXT-ALIGN: center"><B><FONT size=4>UNITED STATES</FONT></B><BR>
    <B><FONT size=4>SECURITIES AND EXCHANGE COMMISSION</FONT></B><BR>
    <B>Washington, D.C. 20549</B></P>
  <P style="TEXT-ALIGN: center"><B><FONT size=5>FORM 6-K</FONT></B></P>
  <P style="TEXT-ALIGN: center"><B>REPORT OF FOREIGN PRIVATE ISSUER <BR>
    PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE<BR>
    </B><B>SECURITIES EXCHANGE ACT OF 1934</B></P>
  <P style="TEXT-ALIGN: center"><B>Dated June 30, 2016</B></P>
  <P style="TEXT-ALIGN: center"><B>Commission File Number 001-36421</B></P>
  <P style="TEXT-ALIGN: center"><B><U><FONT size=6>AURINIA PHARMACEUTICALS INC.</FONT></U><BR>
    </B><B>(Exact name of Registrant as specified in its charter)</B></P>
  <P style="TEXT-ALIGN: center"><B><U>N/A<BR>
    </U></B><B>(Translation of Registrant&#8217;s Name)</B></P>
  <P style="TEXT-ALIGN: center"><B>#1203-4464 Markham Street <BR>
    Victoria, British Columbia <BR>
    V8Z7X8 <BR>
    <U>(250) 708-4272</U><BR>
    </B><B>(Address and telephone number of registrant&#8217;s principal executive offices)</B></P>
  <P style="TEXT-ALIGN: center">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</P>
  <P style="TEXT-ALIGN: center">Form 20-F [&nbsp;&nbsp; ]&nbsp;&nbsp; Form 40-F [ X ]</P>
  <P style="TEXT-ALIGN: center">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (1): [&nbsp;&nbsp; ]</P>
  <P style="TEXT-ALIGN: center">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (7): [&nbsp;&nbsp; ]</P>
  <P style="TEXT-ALIGN: center">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</P>
  <P style="TEXT-ALIGN: center">Yes [&nbsp;&nbsp; ]&nbsp;&nbsp; No [ X ]</P>
  <P style="TEXT-ALIGN: center">If &#8220;Yes&#8221; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.</P>
</DIV>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center SIZE=1 width="100%" noShade>
<BR>
<A name="page_2"></A><BR>
<a name="_bclPageBorder2"></a>
<DIV style="PADDING-LEFT: 0%; PADDING-RIGHT: 0%">
  <P style="TEXT-ALIGN: center"><B>SIGNATURES</B></P>
  <P style="TEXT-ALIGN: justify; TEXT-INDENT: 4%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>
  <P style="TEXT-ALIGN: justify">Dated: June 30, 2016.</P>
  <DIV align=left>
    <TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellSpacing=0 border=0>
      <TR>
        <TD width="50%"></TD>
        <TD width="4%"></TD>
        <TD width="46%"></TD>
      </TR>
      <TR vAlign=bottom>
        <TD width="50%" align=left><B>&nbsp;</B></TD>
        <TD width="50%" colSpan=2 align=left><B></B><B>Aurinia Pharmaceuticals Inc.</B></TD>
      </TR>
      <TR vAlign=bottom>
        <TD width="50%" align=left>&nbsp;</TD>
        <TD width="4%" align=left>By:</TD>
        <TD width="46%" align=left><U>/s/ Dennis Bourgeault</U></TD>
      </TR>
      <TR vAlign=bottom>
        <TD width="50%" align=left>&nbsp;</TD>
        <TD width="4%" align=left>&nbsp;</TD>
        <TD width="46%" align=left>Name: Dennis Bourgeault</TD>
      </TR>
      <TR vAlign=bottom>
        <TD width="50%" align=left>&nbsp;</TD>
        <TD width="4%" align=left>&nbsp;</TD>
        <TD width="46%" align=left>Title: Chief Financial Officer</TD>
      </TR>
    </TABLE>
  </DIV>
  <P style="TEXT-ALIGN: center">2</P>
</DIV>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center SIZE=1 width="100%" noShade>
<BR>
<A name="page_3"></A><BR>
<a name="_bclPageBorder3"></a>
<DIV style="PADDING-LEFT: 0%; PADDING-RIGHT: 0%">
  <P style="TEXT-ALIGN: center"><B>EXHIBIT INDEX</B></P>
  <DIV align=left>
    <TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellSpacing=0 border=0>
      <TR>
        <TD width="10%"></TD>
        <TD width="90%"></TD>
      </TR>
      <TR vAlign=bottom>
        <TD width="10%" align=left><B><U>Exhibit</U></B></TD>
        <TD width="90%" align=left><B><U>Description of Exhibit</U></B></TD>
      </TR>
      <TR vAlign=bottom>
        <TD style="BACKGROUND-COLOR: #ececec" width="10%" align=left><A href="exhibit99-1.htm">99.1</A></TD>
        <TD style="BACKGROUND-COLOR: #ececec" width="90%" align=left><A href="exhibit99-1.htm">Material Change Report dated June 15, 2016</A></TD>
      </TR>
    </TABLE>
  </DIV>
  <P style="TEXT-ALIGN: center">3</P>
</DIV>
<BR>
<HR align=center SIZE=3 width="100%" noShade>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99-1.htm
<DESCRIPTION>MATERIAL CHANGE REPORT DATED JUNE 15, 2016
<TEXT>

<HTML>
<HEAD>
   <TITLE>Exhibit 99.1</TITLE>
</HEAD>

<BODY bgcolor="#ffffff" style="font-family: 'Times New Roman';font-size: 10pt;">

<A name="page_1"></A>

<HR SIZE=3 noShade>



<P style="MARGIN-TOP: 0px" align=right><B>Exhibit 99.1</B></P>

<a name="_bclPageBorder1"></a><DIV style="PADDING-LEFT: 0%; PADDING-RIGHT: 0%">

<P style="TEXT-ALIGN: center"><B>FORM 51-102F3<BR>Material Change Report</B></P>

<DIV align=left>

<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellSpacing=0 border=0>



<TR>

   <TD width="4%"></TD>

   <TD width="96%"></TD></TR>

<TR vAlign=bottom>

   <TD noWrap align=left><B>Item 1</B></TD>

   <TD noWrap align=left><B>Name and Address of Company</B></TD></TR></TABLE></DIV>

<P style="TEXT-ALIGN: justify; MARGIN-LEFT: 4%">Aurinia Pharmaceuticals Inc. (the "<B>Company</B>") #1203-4464 Markham Street Victoria, BC A1 V8Z 7X8</P>

<DIV align=left>

<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellSpacing=0 border=0>



<TR>

   <TD width="4%"></TD>

   <TD width="96%"></TD></TR>

<TR vAlign=bottom>

   <TD noWrap align=left><B>Item 2</B></TD>

   <TD noWrap align=left><B>Date of Material Change</B></TD></TR></TABLE></DIV>

<P style="TEXT-ALIGN: justify; MARGIN-LEFT: 4%">June 15, 2016</P>

<DIV align=left>

<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellSpacing=0 border=0>



<TR>

   <TD width="4%"></TD>

   <TD width="96%"></TD></TR>

<TR vAlign=bottom>

   <TD noWrap align=left><B>Item 3</B></TD>

   <TD noWrap align=left><B>News Release</B></TD></TR></TABLE></DIV>

<P style="TEXT-ALIGN: justify; MARGIN-LEFT: 4%">A news release was issued and disseminated by the Company through Business Wire on June 15, 2016.</P>

<DIV align=left>

<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellSpacing=0 border=0>



<TR>

   <TD width="4%"></TD>

   <TD width="96%"></TD></TR>

<TR vAlign=bottom>

   <TD noWrap align=left><B>Item 4</B></TD>

   <TD noWrap align=left><B>Summary of Material Change</B></TD></TR></TABLE></DIV>

<P style="TEXT-ALIGN: justify; MARGIN-LEFT: 4%">The Company announced, subject to regulatory approval, a US$7,080,000 private placement (the "<B>Offering</B>").</P>

<DIV align=left>

<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellSpacing=0 border=0>



<TR>

   <TD width="4%"></TD>

   <TD width="96%"></TD></TR>

<TR vAlign=bottom>

   <TD noWrap align=left><B>Item 5</B></TD>

   <TD noWrap align=left><B>Full Description of Material Change</B></TD></TR></TABLE></DIV>

<P style="TEXT-ALIGN: justify; MARGIN-LEFT: 4%">On June 15, 2016, the Company announced the Offering. The Company intends to use the net proceeds from the Offering for general corporate purposes, including financing research and development, clinical expenses, and corporate costs.</P>

<P style="TEXT-ALIGN: justify; MARGIN-LEFT: 4%">Under the terms of the Offering, the Company will issue 3,000,000 units (the "<B>Units</B>") at a subscription price per Unit of US$2.36, each Unit consisting of one common share (&#8220;<B>Common Share</B>&#8221;) and 0.35 of one common share purchase warrant (each full warrant, a &#8220;<B>Warrant</B>&#8221;), with each Warrant exercisable for a period of 24 months from the date of closing of the Offering at an exercise price of US$2.77.</P>

<P style="TEXT-ALIGN: justify; MARGIN-LEFT: 4%">Canaccord Genuity Inc. acted as placement agent for the Offering.</P>

<DIV align=left>

<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellSpacing=0 border=0>



<TR>

   <TD width="4%"></TD>

   <TD width="96%"></TD></TR>

<TR vAlign=bottom>

   <TD noWrap align=left><B>Item 5.2</B></TD>

   <TD noWrap align=left><B>Disclosure of Restructuring Transactions</B></TD></TR></TABLE></DIV>

<P style="TEXT-ALIGN: justify; MARGIN-LEFT: 4%">Not applicable.</P>

<DIV align=left>

<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellSpacing=0 border=0>



<TR>

   <TD width="4%"></TD>

   <TD width="96%"></TD></TR>

<TR vAlign=bottom>

   <TD noWrap align=left><B>Item 6</B></TD>

   <TD noWrap align=left><B>Reliance on subsection 7.1(2) of National Instrument 51-102</B></TD></TR></TABLE></DIV>

<P style="TEXT-ALIGN: justify; MARGIN-LEFT: 4%">Not applicable.</P>

<DIV align=left>

<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellSpacing=0 border=0>



<TR>

   <TD width="4%"></TD>

   <TD width="96%"></TD></TR>

<TR vAlign=bottom>

   <TD noWrap align=left><B>Item 7</B></TD>

   <TD noWrap align=left><B>Omitted Information</B></TD></TR></TABLE></DIV>

<P style="TEXT-ALIGN: justify; MARGIN-LEFT: 4%">No significant facts remain confidential in, and no information has been omitted from, this report.</P></DIV><BR>

<HR style="PAGE-BREAK-AFTER: always" align=center SIZE=1 width="100%" noShade>

<BR>

<A name="page_2"></A><BR>

<a name="_bclPageBorder2"></a><DIV style="PADDING-LEFT: 0%; PADDING-RIGHT: 0%">

<DIV align=left>

<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellSpacing=0 border=0>



<TR>

   <TD width="4%"></TD>

   <TD width="96%"></TD></TR>

<TR vAlign=bottom>

   <TD noWrap align=left><B>Item 8</B></TD>

   <TD noWrap align=left><B>Executive Officer</B></TD></TR></TABLE></DIV>

<P style="TEXT-ALIGN: justify; MARGIN-LEFT: 4%">For further information, please contact:</P>

<P style="TEXT-ALIGN: justify; MARGIN-LEFT: 4%">Mr. Michael R. Martin, Chief Operating Officer <BR>250-415-9713 <BR>mmartin@auriniapharma.com</P>

<DIV align=left>

<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellSpacing=0 border=0>



<TR>

   <TD width="4%"></TD>

   <TD width="96%"></TD></TR>

<TR vAlign=bottom>

   <TD noWrap align=left><B>Item 9</B></TD>

   <TD noWrap align=left><B>Date of Report</B></TD></TR></TABLE></DIV>

<P style="TEXT-ALIGN: justify; MARGIN-LEFT: 4%">June 23, 2016</P></DIV><BR>

<HR align=center SIZE=3 width="100%" noShade>



</BODY>

</HTML>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
